13 years with research activity and no counted money; 0 with money and no papers or trials.
NIH only in v0; non-NIH funder award lists (pipeline gap 3) are not loaded yet. Rows are topics until approach facets land. Funders counted: National Institutes of Health, NIAAA, NIA, NIAID, NCCIH, NIH BC, NIH BX, NCI, NIDDK, NIBIB, NIEHS, NIGMS, NICHD, NHGRI, NHLBI, NIH HX, NINDS, NIH OD, NIH RD, NCRR, NIH SC, NCATS.
Gap heatmap
Fill: counted dollars that year (log scale; grey = none). Ring: papers plus trials started. Dashed rust outline: activity with no counted money. Diagonal line: money with no papers or trials.
Not in the data yet: approach rows. The knowledge layer returns topics as rows until approach facets land, so the heatmap can’t yet split KRAS into G12C, G12D and the rest.
Not in the data yet: funders other than NIH. Stephenson, PanCAN, Lustgarten and DoD CDMRP award lists (knowledge gap K3) will add rows per funder.
National Institutes of Health: $1045M counted
| Grant | Institution | PIs | Fiscal years | Counted | Flags |
|---|---|---|---|---|---|
| DP1CA228041↗ Enhancer RNA Therapy | University Of Miami School Of Medicine | Ramin Shiekhattar | 2017–2021 | $5,372,500 | |
| DP2CA228042↗ Dissecting tumor metabolic heterogeneity in vivo | Rockefeller University | Kivanc Birsoy | 2017–2017 | $2,542,500 | |
| DP3DK094343↗ T1D:Investigating the Gut Microbiome, Urinary Proteome and Metabolome | J. Craig Venter Institute, Inc. | Rembert Pieper | 2011–2011 | $4,700,934 | |
| F30CA167963↗ Defining PI3K p110alpha as a therapeutic target in pancreatic cancer | State University New York Stony Brook | Eileen S Carpenter | 2012–2014 | $107,127 | |
| F30CA168063↗ Roles of MiR-17-92 Cluster MicroRNAs in K-Ras-Induced Pancreatic Tumorigenesis |